-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 9th, the CDE official website showed that Fosun Kate Akirensai injection is planned to be included in the list of breakthrough treatment products.
On June 23, the State Food and Drug Administration has approved a new drug application for Akirensai injection, which is the first cell therapy product approved for marketing in China for the treatment of relapses after previous second-line or above systemic treatments Or refractory large B-cell lymphoma (r/r LBCL) adult patients, including diffuse large B-cell lymphoma (DLBCL) non-specific (NOS), primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma and follicular lymphoma transformed DLBCL1